Share:
WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the "
Company" or "
WPD") a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10
th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021.
During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: "New approach to glioblastoma treatment addressing the critical unmet medical need", granted by National Research and Development Center ("
NRDC") and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020.